Granisetron

Generic name: Pronounced as (gra ni' se tron)
Brand names
  • Kytril®
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 06/15/2016

Granisetron is used to prevent nausea and vomiting caused by cancer chemotherapy and radiation therapy. Granisetron is in a class of medications called 5-HT3 receptor antagonists. It works by blocking serotonin, a natural substance in the body that causes nausea and vomiting.

Granisetron comes as a tablet to take by mouth. When taken to prevent nausea and vomiting caused by chemotherapy, granisetron is usually taken 1 hour before chemotherapy is begun. A second dose may be taken 12 hours after the first dose depending on the strength. When taken to prevent nausea and vomiting caused by radiation, granisetron is usually taken within 1 hour before treatment. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take granisetron exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Before taking granisetron,

  • tell your doctor and pharmacist if you are allergic to granisetron, alosetron (Lotronex), dolasetron (Anzemet), ondansetron (Zofran, Zuplenz), palonosetron (Aloxi, in Akynzeo), any other medications, or any of the ingredients in granisetron tablets. Ask your pharmacist for a list of the ingredients.

  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking. Be sure to mention any of the following: fentanyl (Abstral, Actiq, Duragesic, Fentora, Lazanda, Onsolis, Subsys); ketoconazole (Nizoral), lithium (Lithobid); medications to treat migraines such as almotriptan (Axert), eletriptan (Relpax), frovatriptan (Frova), naratriptan (Amerge), rizatriptan (Maxalt), sumatriptan (Imitrex), and zolmitriptan (Zomig); methylene blue; mirtazapine (Remeron); monoamine oxidase (MAO) inhibitors including isocarboxazid (Marplan), linezolid (Zyvox), phenelzine (Nardil), selegiline (Eldepryl, Emsam, Zelapar), and tranylcypromine (Parnate); phenobarbital; selective serotonin reuptake inhibitors (SSRIs) such as citalopram (Celexa), escitalopram (Lexapro), fluoxetine (Prozac, Sarafem, in Symbyax), fluvoxamine (Luvox), paroxetine (Brisdelle, Paxil, Pexeva), and sertraline (Zoloft); and tramadol (Conzip, Ultram, in Ultracet). Your doctor may need to change the doses of your medications or monitor you carefully for side effects.

  • tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. If you become pregnant while taking granisetron, call your doctor.

Unless your doctor tells you otherwise, continue your normal diet.

Granisetron should only be taken before chemotherapy or radiation therapy, as instructed by your doctor. It should not be taken on a regularly scheduled basis.

  • Granisetron may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • headache

    • stomach pain

    • heartburn

    • constipation

    • difficulty falling asleep or staying asleep

  • Some side effects can be serious. If you experience any of the following symptoms, call your doctor immediately or seek emergency medical treatment:

    • hives

    • rash

    • itching

    • difficulty breathing or swallowing

    • shortness of breath

    • dizziness, light-headedness, or fainting

    • fast, slow or irregular heartbeat

    • agitation

    • hallucinations (seeing things or hearing voices that do not exist)

    • fever

    • flushing

    • excessive sweating

    • confusion

    • nausea, vomiting, or diarrhea

    • loss of coordination

    • stiff or twitching muscles

    • seizures

    • coma (loss of consciousness)

  • Granisetron may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom).

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Symptoms of overdose may include the following:

  • headache

Keep all appointments with your doctor.

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug Interaction
Moxifloxacin Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Granisetron.
Dolasetron Dolasetron The risk or severity of adverse effects can be increased when Dolasetron is combined with Granisetron.
Anagrelide Anagrelide The risk or severity of QTc prolongation can be increased when Granisetron is combined with Anagrelide.
Cilostazol Cilostazol The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Granisetron.
Diphenoxylate Diphenoxylate The risk or severity of adverse effects can be increased when Granisetron is combined with Diphenoxylate.
Erythromycin and Sulfisoxazole Erythromycin and Sulfisoxazole The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Granisetron.
Guanfacine Guanfacine The risk or severity of adverse effects can be increased when Granisetron is combined with Guanfacine.
Naratriptan Naratriptan The risk or severity of adverse effects can be increased when Granisetron is combined with Naratriptan.
Paregoric Paregoric The risk or severity of adverse effects can be increased when Morphine is combined with Granisetron.
Penbutolol Penbutolol The risk or severity of QTc prolongation can be increased when Granisetron is combined with Acebutolol.
Pentazocine Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Granisetron.
Reserpine Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Granisetron.
Rizatriptan Rizatriptan The risk or severity of adverse effects can be increased when Granisetron is combined with Rizatriptan.
Sumatriptan Sumatriptan The risk or severity of adverse effects can be increased when Sumatriptan is combined with Granisetron.
Tacrolimus Tacrolimus The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Granisetron.
Tizanidine Tizanidine The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Granisetron.
Zolmitriptan Zolmitriptan The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Granisetron.
Famotidine Injection Famotidine Injection The risk or severity of QTc prolongation can be increased when Famotidine is combined with Granisetron.
Fluconazole Injection Fluconazole Injection The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Granisetron.
Foscarnet Injection Foscarnet Injection The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Granisetron.
Hydromorphone Injection Hydromorphone Injection The risk or severity of adverse effects can be increased when Hydromorphone is combined with Granisetron.
Levofloxacin Injection Levofloxacin Injection The risk or severity of QTc prolongation can be increased when Granisetron is combined with Levofloxacin.
Meperidine Injection Meperidine Injection The risk or severity of adverse effects can be increased when Meperidine is combined with Granisetron.
Metoclopramide Injection Metoclopramide Injection The risk or severity of sedation can be increased when Granisetron is combined with Metoclopramide.
Metronidazole Injection Metronidazole Injection The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Granisetron.
Morphine Injection Morphine Injection The risk or severity of adverse effects can be increased when Morphine is combined with Granisetron.
Altretamine Altretamine The risk or severity of adverse effects can be increased when Amphetamine is combined with Granisetron.
Ondansetron Ondansetron The risk or severity of adverse effects can be increased when Granisetron is combined with Ondansetron.
Olanzapine Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Granisetron.
Alosetron Alosetron The risk or severity of adverse effects can be increased when Granisetron is combined with Alosetron.
Dofetilide Dofetilide The risk or severity of QTc prolongation can be increased when Granisetron is combined with Dofetilide.
Entacapone Entacapone The risk or severity of adverse effects can be increased when Entacapone is combined with Granisetron.
Hydroxychloroquine Hydroxychloroquine The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Granisetron.
Oxcarbazepine Oxcarbazepine The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Granisetron.
Zaleplon Zaleplon The risk or severity of adverse effects can be increased when Granisetron is combined with Zaleplon.
Desloratadine Desloratadine The risk or severity of QTc prolongation can be increased when Granisetron is combined with Desloratadine.
Linezolid Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Granisetron.
Trimipramine Trimipramine The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Granisetron.
Glycopyrrolate Glycopyrrolate Granisetron may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.
Escitalopram Escitalopram The risk or severity of serotonin syndrome can be increased when Granisetron is combined with Escitalopram.
Zonisamide Zonisamide The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Granisetron.
Aripiprazole Aripiprazole The risk or severity of adverse effects can be increased when Granisetron is combined with Aripiprazole.
Atomoxetine Atomoxetine The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Granisetron.
Dexmethylphenidate Dexmethylphenidate The risk or severity of adverse effects can be increased when Granisetron is combined with Dexmethylphenidate.
Atazanavir Atazanavir The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Granisetron.
Almotriptan Almotriptan The risk or severity of adverse effects can be increased when Granisetron is combined with Almotriptan.
Eletriptan Eletriptan The risk or severity of adverse effects can be increased when Eletriptan is combined with Granisetron.
Mefloquine Mefloquine The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Granisetron.
Vardenafil Vardenafil The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Granisetron.
Alfuzosin Alfuzosin The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Granisetron.
Tegaserod Tegaserod The risk or severity of serotonin syndrome can be increased when Granisetron is combined with Tegaserod.
Frovatriptan Frovatriptan The risk or severity of adverse effects can be increased when Granisetron is combined with Frovatriptan.
Gemifloxacin Gemifloxacin The risk or severity of QTc prolongation can be increased when Granisetron is combined with Gemifloxacin.
Apomorphine Injection Apomorphine Injection The risk or severity of hypotension can be increased when Apomorphine is combined with Granisetron.
Protriptyline Protriptyline The risk or severity of adverse effects can be increased when Protriptyline is combined with Granisetron.
Duloxetine Duloxetine The risk or severity of adverse effects can be increased when Granisetron is combined with Duloxetine.
Trospium Trospium Granisetron may increase the central nervous system depressant (CNS depressant) activities of Trospium.
Erlotinib Erlotinib The risk or severity of QTc prolongation can be increased when Granisetron is combined with Erlotinib.
Eszopiclone Eszopiclone The risk or severity of CNS depression can be increased when Granisetron is combined with Eszopiclone.
Solifenacin Solifenacin The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Granisetron.
Voriconazole Voriconazole The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Granisetron.
Dextroamphetamine Dextroamphetamine The risk or severity of adverse effects can be increased when Amphetamine is combined with Granisetron.
Sodium Oxybate Sodium Oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Granisetron.
Ibandronate Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Granisetron.
Isocarboxazid Isocarboxazid The risk or severity of adverse effects can be increased when Granisetron is combined with Isocarboxazid.
Ramelteon Ramelteon The risk or severity of adverse effects can be increased when Granisetron is combined with Ramelteon.
Darifenacin Darifenacin Granisetron may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.
Fentanyl Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Granisetron.
Pregabalin Pregabalin The therapeutic efficacy of Granisetron can be increased when used in combination with Pregabalin.
Felbamate Felbamate The risk or severity of QTc prolongation can be increased when Felbamate is combined with Granisetron.
Ranolazine Ranolazine The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Granisetron.
Rasagiline Rasagiline The risk or severity of adverse effects can be increased when Granisetron is combined with Rasagiline.
Imatinib Imatinib The risk or severity of QTc prolongation can be increased when Granisetron is combined with Imatinib.
Albuterol Albuterol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Granisetron.
Paliperidone Paliperidone The risk or severity of QTc prolongation can be increased when Granisetron is combined with Paliperidone.
Bortezomib Bortezomib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Granisetron.
Oxaliplatin Injection Oxaliplatin Injection The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Granisetron.
Posaconazole Posaconazole The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Granisetron.
Primaquine Primaquine The risk or severity of QTc prolongation can be increased when Granisetron is combined with Primaquine.
Dimenhydrinate Dimenhydrinate The risk or severity of QTc prolongation can be increased when Granisetron is combined with Dimenhydrinate.
Lisdexamfetamine Lisdexamfetamine The risk or severity of serotonin syndrome can be increased when Granisetron is combined with Lisdexamfetamine.
Nabilone Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Granisetron.
Vorinostat Vorinostat The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Granisetron.
Sorafenib Sorafenib The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Granisetron.
Sunitinib Sunitinib The risk or severity of QTc prolongation and torsade de pointes can be increased when Sunitinib is combined with Granisetron.
Dronabinol Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Granisetron.
Lapatinib Lapatinib The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Granisetron.
Levocetirizine Levocetirizine The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Granisetron.
Dasatinib Dasatinib The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Granisetron.
Nilotinib Nilotinib The risk or severity of QTc prolongation can be increased when Granisetron is combined with Nilotinib.
Toremifene Toremifene The risk or severity of QTc prolongation can be increased when Granisetron is combined with Toremifene.
OnabotulinumtoxinA Injection OnabotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Granisetron.
RimabotulinumtoxinB Injection RimabotulinumtoxinB Injection The risk or severity of adverse effects can be increased when Botulinum Toxin Type B is combined with Granisetron.
Arsenic Trioxide Injection Arsenic Trioxide Injection The risk or severity of QTc prolongation can be increased when Granisetron is combined with Arsenic trioxide.
Desvenlafaxine Desvenlafaxine The risk or severity of adverse effects can be increased when Granisetron is combined with Desvenlafaxine.
Flecainide Flecainide The risk or severity of QTc prolongation can be increased when Granisetron is combined with Flecainide.
Rufinamide Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Granisetron.
Midazolam Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Granisetron.
Naltrexone Injection Naltrexone Injection The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Granisetron.
Milnacipran Milnacipran The risk or severity of adverse effects can be increased when Granisetron is combined with Milnacipran.
Fesoterodine Fesoterodine Granisetron may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.
Degarelix Injection Degarelix Injection The risk or severity of QTc prolongation can be increased when Degarelix is combined with Granisetron.
Betaxolol Betaxolol The risk or severity of QTc prolongation can be increased when Betaxolol is combined with Granisetron.
Iloperidone Iloperidone The risk or severity of QTc prolongation can be increased when Granisetron is combined with Iloperidone.
Lacosamide Lacosamide The risk or severity of adverse effects can be increased when Granisetron is combined with Lacosamide.
Dronedarone Dronedarone The risk or severity of QTc prolongation can be increased when Granisetron is combined with Dronedarone.
AbobotulinumtoxinA Injection AbobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Granisetron.
Palonosetron Injection Palonosetron Injection The risk or severity of adverse effects can be increased when Palonosetron is combined with Granisetron.
Telavancin Injection Telavancin Injection The risk or severity of QTc prolongation can be increased when Granisetron is combined with Telavancin.
Romidepsin Injection Romidepsin Injection The risk or severity of QTc prolongation can be increased when Granisetron is combined with Romidepsin.
Tapentadol Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Granisetron.
Pazopanib Pazopanib The risk or severity of QTc prolongation can be increased when Granisetron is combined with Pazopanib.
Asenapine Asenapine The risk or severity of QTc prolongation can be increased when Granisetron is combined with Asenapine.
Vigabatrin Vigabatrin The risk or severity of adverse effects can be increased when Granisetron is combined with Vigabatrin.
Oxymorphone Oxymorphone The risk or severity of adverse effects can be increased when Granisetron is combined with Oxymorphone.
Eribulin Injection Eribulin Injection The risk or severity of QTc prolongation can be increased when Eribulin is combined with Granisetron.
IncobotulinumtoxinA Injection IncobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Botulinum toxin type A is combined with Granisetron.
Lurasidone Lurasidone The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Granisetron.
Vilazodone Vilazodone The risk or severity of adverse effects can be increased when Granisetron is combined with Vilazodone.
Terbutaline Injection Terbutaline Injection The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Granisetron.
Rilpivirine Rilpivirine The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Granisetron.
Triptorelin Injection Triptorelin Injection The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Granisetron.
Vandetanib Vandetanib The risk or severity of QTc prolongation can be increased when Granisetron is combined with Vandetanib.
Clobazam Clobazam The risk or severity of adverse effects can be increased when Clobazam is combined with Granisetron.
Vemurafenib Vemurafenib The risk or severity of QTc prolongation can be increased when Granisetron is combined with Vemurafenib.
Crizotinib Crizotinib The risk or severity of QTc prolongation can be increased when Granisetron is combined with Crizotinib.
Cabergoline Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Granisetron.
Ezogabine Ezogabine The risk or severity of adverse effects can be increased when Granisetron is combined with Tiagabine.
Mirabegron Mirabegron The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Granisetron.
Bedaquiline Bedaquiline The risk or severity of QTc prolongation can be increased when Granisetron is combined with Bedaquiline.
Pomalidomide Pomalidomide The risk or severity of adverse effects can be increased when Granisetron is combined with Pomalidomide.
Dabrafenib Dabrafenib The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Granisetron.
Levomilnacipran Levomilnacipran The risk or severity of adverse effects can be increased when Granisetron is combined with Levomilnacipran.
Vortioxetine Vortioxetine The risk or severity of adverse effects can be increased when Granisetron is combined with Vortioxetine.
Perampanel Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Granisetron.
Ceritinib Ceritinib The risk or severity of QTc prolongation can be increased when Granisetron is combined with Ceritinib.
Eslicarbazepine Eslicarbazepine The risk or severity of adverse effects can be increased when Granisetron is combined with Eslicarbazepine.
Hydrocodone Hydrocodone Hydrocodone may increase the central nervous system depressant (CNS depressant) activities of Granisetron.
Suvorexant Suvorexant Granisetron may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Methamphetamine Methamphetamine The risk or severity of adverse effects can be increased when Granisetron is combined with Metamfetamine.
Tasimelteon Tasimelteon The risk or severity of adverse effects can be increased when Granisetron is combined with Tasimelteon.
Risperidone Injection Risperidone Injection The risk or severity of adverse effects can be increased when Risperidone is combined with Granisetron.
Lenvatinib Lenvatinib The risk or severity of QTc prolongation can be increased when Granisetron is combined with Lenvatinib.
Panobinostat Panobinostat The risk or severity of QTc prolongation can be increased when Granisetron is combined with Panobinostat.
Haloperidol Injection Haloperidol Injection The risk or severity of QTc prolongation can be increased when Haloperidol is combined with Granisetron.
Ivabradine Ivabradine Ivabradine may increase the QTc-prolonging activities of Granisetron.
Flibanserin Flibanserin The risk or severity of adverse effects can be increased when Granisetron is combined with Flibanserin.
Brexpiprazole Brexpiprazole The risk or severity of adverse effects can be increased when Granisetron is combined with Brexpiprazole.
Ziprasidone Injection Ziprasidone Injection The risk or severity of QTc prolongation can be increased when Granisetron is combined with Ziprasidone.
Cariprazine Cariprazine The risk or severity of adverse effects can be increased when Granisetron is combined with Cariprazine.
Eluxadoline Eluxadoline The risk or severity of serotonin syndrome can be increased when Granisetron is combined with Eluxadoline.
Brivaracetam Injection Brivaracetam Injection The risk or severity of adverse effects can be increased when Granisetron is combined with Brivaracetam.
Pimavanserin Pimavanserin The risk or severity of adverse effects can be increased when Granisetron is combined with Pimavanserin.
Diphenhydramine Injection Diphenhydramine Injection The risk or severity of adverse effects can be increased when Granisetron is combined with Diphenhydramine.
Ribociclib Ribociclib The risk or severity of QTc prolongation can be increased when Granisetron is combined with Ribociclib.
Doxepin (Insomnia) Doxepin (Insomnia) The risk or severity of QTc prolongation can be increased when Doxepin is combined with Granisetron.
Deutetrabenazine Deutetrabenazine The risk or severity of QTc prolongation can be increased when Granisetron is combined with Deutetrabenazine.
Safinamide Safinamide The risk or severity of adverse effects can be increased when Granisetron is combined with Safinamide.
Delafloxacin Delafloxacin The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Granisetron.
Tetrabenazine Tetrabenazine The risk or severity of QTc prolongation can be increased when Granisetron is combined with Tetrabenazine.
Buprenorphine Injection Buprenorphine Injection Granisetron may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Lofexidine Lofexidine The therapeutic efficacy of Granisetron can be increased when used in combination with Lofexidine.
Eliglustat Eliglustat The risk or severity of QTc prolongation can be increased when Granisetron is combined with Eliglustat.
Encorafenib Encorafenib The risk or severity of QTc prolongation can be increased when Granisetron is combined with Encorafenib.
Ivosidenib Ivosidenib The risk or severity of QTc prolongation can be increased when Granisetron is combined with Ivosidenib.
Cannabidiol Cannabidiol The risk or severity of adverse effects can be increased when Cannabidiol is combined with Granisetron.
Stiripentol Stiripentol The risk or severity of adverse effects can be increased when Granisetron is combined with Stiripentol.
Gilteritinib Gilteritinib The therapeutic efficacy of Granisetron can be decreased when used in combination with Gilteritinib.
Glasdegib Glasdegib The risk or severity of QTc prolongation can be increased when Granisetron is combined with Glasdegib.
Brexanolone Injection Brexanolone Injection The risk or severity of adverse effects can be increased when Granisetron is combined with Brexanolone.
Solriamfetol Solriamfetol The risk or severity of adverse effects can be increased when Granisetron is combined with Solriamfetol.
Triclabendazole Triclabendazole The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Granisetron.
Entrectinib Entrectinib The risk or severity of QTc prolongation can be increased when Granisetron is combined with Entrectinib.
Pitolisant Pitolisant The serum concentration of Granisetron can be decreased when it is combined with Pitolisant.
Lefamulin Lefamulin Lefamulin may increase the QTc-prolonging activities of Granisetron.
Phenytoin Injection Phenytoin Injection The risk or severity of adverse effects can be increased when Phenytoin is combined with Granisetron.
Fosphenytoin Injection Fosphenytoin Injection The risk or severity of adverse effects can be increased when Granisetron is combined with Fosphenytoin.
Lumateperone Lumateperone The risk or severity of adverse effects can be increased when Granisetron is combined with Lumateperone.
Lasmiditan Lasmiditan The risk or severity of serotonin syndrome can be increased when Granisetron is combined with Lasmiditan.
Cenobamate Cenobamate The serum concentration of Granisetron can be decreased when it is combined with Cenobamate.
Tucatinib Tucatinib The metabolism of Tucatinib can be decreased when combined with Granisetron.
Lemborexant Lemborexant The risk or severity of adverse effects can be increased when Granisetron is combined with Lemborexant.
Fenfluramine Fenfluramine The risk or severity of serotonin syndrome can be increased when Fenfluramine is combined with Granisetron.
Fostemsavir Fostemsavir The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Granisetron.
Octreotide Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Granisetron.
Satralizumab-mwge Injection Satralizumab-mwge Injection The serum concentration of Granisetron can be decreased when it is combined with Satralizumab.
Relugolix Relugolix The risk or severity of QTc prolongation can be increased when Relugolix is combined with Granisetron.
Viloxazine Viloxazine The risk or severity of adverse effects can be increased when Granisetron is combined with Viloxazine.
Trazodone Trazodone The risk or severity of QTc prolongation can be increased when Trazodone is combined with Granisetron.
Phenobarbital Phenobarbital The risk or severity of adverse effects can be increased when Granisetron is combined with Phenobarbital.
Metaxalone Metaxalone The risk or severity of adverse effects can be increased when Metaxalone is combined with Granisetron.
Levorphanol Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Granisetron.
Primidone Primidone The risk or severity of adverse effects can be increased when Primidone is combined with Granisetron.
Methsuximide Methsuximide The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Granisetron.
Diethylpropion Diethylpropion The risk or severity of adverse effects can be increased when Granisetron is combined with Diethylpropion.
Chlorpromazine Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Granisetron.
Diazepam Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Granisetron.
Oxazepam Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Granisetron.
Flurazepam Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Granisetron.
Clorazepate Clorazepate The risk or severity of adverse effects can be increased when Clorazepic acid is combined with Granisetron.
Lorazepam Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Granisetron.
Amantadine Amantadine The risk or severity of serotonin syndrome can be increased when Granisetron is combined with Amantadine.
Codeine Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Granisetron.
Meprobamate Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Granisetron.
Chlordiazepoxide Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Granisetron.
Bromocriptine Bromocriptine The risk or severity of adverse effects can be increased when Granisetron is combined with Bromocriptine.
Tranylcypromine Tranylcypromine The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Granisetron.
Phenelzine Phenelzine The risk or severity of adverse effects can be increased when Phenelzine is combined with Granisetron.
Procarbazine Procarbazine The risk or severity of adverse effects can be increased when Granisetron is combined with Procarbazine.
Ergoloid Mesylates Ergoloid Mesylates The risk or severity of adverse effects can be increased when Granisetron is combined with Ergoloid mesylate.
Minocycline Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Granisetron.
Prochlorperazine Prochlorperazine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Granisetron.
Thioridazine Thioridazine The risk or severity of QTc prolongation can be increased when Granisetron is combined with Thioridazine.
Trifluoperazine Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Granisetron.
Oxycodone Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Granisetron.
Methadone Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Granisetron.
Oxybutynin Oxybutynin Granisetron may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.
Benztropine Benztropine The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Granisetron.
Maprotiline Maprotiline The risk or severity of adverse effects can be increased when Granisetron is combined with Maprotiline.
Trihexyphenidyl Trihexyphenidyl Granisetron may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.
Orphenadrine Orphenadrine Granisetron may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Perphenazine Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Granisetron.
Fluphenazine Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Granisetron.
Phentermine Phentermine The risk or severity of serotonin syndrome can be increased when Phentermine is combined with Granisetron.
Amoxapine Amoxapine The risk or severity of adverse effects can be increased when Amoxapine is combined with Granisetron.
Carbamazepine Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Granisetron.
Molindone Molindone The risk or severity of adverse effects can be increased when Granisetron is combined with Molindone.
Clonidine Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Granisetron.
Warfarin Warfarin The risk or severity of adverse effects can be increased when Granisetron is combined with Warfarin.
Clonazepam Clonazepam The risk or severity of adverse effects can be increased when Granisetron is combined with Clonazepam.
Loperamide Loperamide The risk or severity of QTc prolongation can be increased when Loperamide is combined with Granisetron.
Promethazine Promethazine The risk or severity of adverse effects can be increased when Granisetron is combined with Promethazine.
Digoxin Digoxin The risk or severity of QTc prolongation can be increased when Digoxin is combined with Granisetron.
Loxapine Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Granisetron.
Chloroquine Chloroquine The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Granisetron.
Quinine Quinine The risk or severity of QTc prolongation can be increased when Granisetron is combined with Quinine.
Ethosuximide Ethosuximide The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Granisetron.
Secobarbital Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Granisetron.
Desipramine Desipramine The risk or severity of adverse effects can be increased when Granisetron is combined with Desipramine.
Amitriptyline Amitriptyline The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Granisetron.
Imipramine Imipramine The risk or severity of QTc prolongation can be increased when Imipramine is combined with Granisetron.
Quinidine Quinidine The risk or severity of QTc prolongation can be increased when Granisetron is combined with Quinidine.
Procainamide Procainamide The risk or severity of QTc prolongation can be increased when Granisetron is combined with Procainamide.
Isoniazid Isoniazid The risk or severity of serotonin syndrome can be increased when Granisetron is combined with Isoniazid.
Disopyramide Disopyramide The risk or severity of QTc prolongation can be increased when Granisetron is combined with Disopyramide.
Valproic Acid Valproic Acid The risk or severity of QTc prolongation can be increased when Granisetron is combined with Valproic acid.
Tamoxifen Tamoxifen The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Granisetron.
Butabarbital Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Granisetron.
Dextromethorphan Dextromethorphan The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Granisetron.
Cyclobenzaprine Cyclobenzaprine The risk or severity of CNS depression can be increased when Granisetron is combined with Cyclobenzaprine.
Baclofen Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Granisetron.
Doxylamine Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Granisetron.
Cyproheptadine Cyproheptadine The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Granisetron.
Clemastine Clemastine The risk or severity of QTc prolongation can be increased when Granisetron is combined with Clemastine.
Chlorpheniramine Chlorpheniramine The risk or severity of adverse effects can be increased when Granisetron is combined with Chlorpheniramine.
Brompheniramine Brompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Granisetron.
Meclizine Meclizine The risk or severity of adverse effects can be increased when Meclizine is combined with Granisetron.
Hydrochlorothiazide Hydrochlorothiazide The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Granisetron.
Dantrolene Dantrolene The risk or severity of adverse effects can be increased when Granisetron is combined with Dantrolene.
Chlorzoxazone Chlorzoxazone The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Granisetron.
Carisoprodol Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Granisetron.
Methocarbamol Methocarbamol The risk or severity of adverse effects can be increased when Methocarbamol is combined with Granisetron.
Disulfiram Disulfiram The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Granisetron.
Propranolol (Cardiovascular) Propranolol (Cardiovascular) The risk or severity of QTc prolongation can be increased when Propranolol is combined with Granisetron.
Pseudoephedrine Pseudoephedrine The risk or severity of serotonin syndrome can be increased when Pseudoephedrine is combined with Granisetron.
Nortriptyline Nortriptyline The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Granisetron.
Butorphanol Injection Butorphanol Injection The risk or severity of adverse effects can be increased when Butorphanol is combined with Granisetron.
Nalbuphine Injection Nalbuphine Injection The risk or severity of adverse effects can be increased when Nalbuphine is combined with Granisetron.
Oxytocin Injection Oxytocin Injection The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Granisetron.
Trimethobenzamide Trimethobenzamide The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Granisetron.
Flavoxate Flavoxate Granisetron may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.
Papaverine Papaverine The risk or severity of QTc prolongation can be increased when Granisetron is combined with Papaverine.
Fluorouracil Injection Fluorouracil Injection The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Granisetron.
Acetazolamide Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Granisetron.
Ketoconazole Ketoconazole The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Granisetron.
Pyrantel Pyrantel The risk or severity of adverse effects can be increased when Granisetron is combined with Pyrantel.
Hydroxyzine Hydroxyzine The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Granisetron.
Thiothixene Thiothixene The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Granisetron.
Alprazolam Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Granisetron.
Temazepam Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Granisetron.
Triazolam Triazolam The risk or severity of adverse effects can be increased when Granisetron is combined with Triazolam.
Dicyclomine Dicyclomine Granisetron may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.
Hyoscyamine Hyoscyamine The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Granisetron.
Propantheline Propantheline Granisetron may increase the central nervous system depressant (CNS depressant) activities of Propantheline.
Diltiazem Diltiazem The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Granisetron.
Nifedipine Nifedipine The risk or severity of QTc prolongation can be increased when Granisetron is combined with Nifedipine.
Timolol Timolol The risk or severity of QTc prolongation can be increased when Timolol is combined with Granisetron.
Pindolol Pindolol The risk or severity of adverse effects can be increased when Granisetron is combined with Pindolol.
Indapamide Indapamide The risk or severity of QTc prolongation can be increased when Indapamide is combined with Granisetron.
Pentamidine Injection Pentamidine Injection The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Granisetron.
Leuprolide Injection Leuprolide Injection The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Granisetron.
Pimozide Pimozide The risk or severity of QTc prolongation can be increased when Granisetron is combined with Pimozide.
Amiodarone Amiodarone The risk or severity of QTc prolongation can be increased when Granisetron is combined with Amiodarone.
Buspirone Buspirone The risk or severity of serotonin syndrome can be increased when Buspirone is combined with Granisetron.
Ciprofloxacin Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Granisetron.
Fluoxetine Fluoxetine The risk or severity of serotonin syndrome can be increased when Granisetron is combined with Fluoxetine.
Nimodipine Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Granisetron.
Clozapine Clozapine The risk or severity of QTc prolongation can be increased when Clozapine is combined with Granisetron.
Estazolam Estazolam The risk or severity of adverse effects can be increased when Granisetron is combined with Estazolam.
Ofloxacin Ofloxacin The risk or severity of QTc prolongation can be increased when Granisetron is combined with Ofloxacin.
Clarithromycin Clarithromycin The risk or severity of QTc prolongation can be increased when Granisetron is combined with Clarithromycin.
Felodipine Felodipine The risk or severity of QTc prolongation can be increased when Felodipine is combined with Granisetron.
Itraconazole Itraconazole The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Granisetron.
Sotalol Sotalol The risk or severity of QTc prolongation can be increased when Granisetron is combined with Sotalol.
Zolpidem Zolpidem Granisetron may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Isradipine Isradipine The risk or severity of QTc prolongation can be increased when Isradipine is combined with Granisetron.
Cisapride Cisapride The risk or severity of QTc prolongation can be increased when Granisetron is combined with Cisapride.
Gabapentin Gabapentin The risk or severity of adverse effects can be increased when Granisetron is combined with Gabapentin.
Venlafaxine Venlafaxine The risk or severity of adverse effects can be increased when Venlafaxine is combined with Granisetron.
Fluvoxamine Fluvoxamine The risk or severity of adverse effects can be increased when Granisetron is combined with Fluvoxamine.
Nefazodone Nefazodone The risk or severity of adverse effects can be increased when Nefazodone is combined with Granisetron.
Lamotrigine Lamotrigine The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Granisetron.
Losartan Losartan The risk or severity of QTc prolongation can be increased when Losartan is combined with Granisetron.
Tramadol Tramadol The risk or severity of serotonin syndrome can be increased when Granisetron is combined with Tramadol.
Moexipril Moexipril The risk or severity of QTc prolongation can be increased when Moexipril is combined with Granisetron.
Nicardipine Nicardipine The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Granisetron.
Bupropion Bupropion The risk or severity of adverse effects can be increased when Granisetron is combined with Bupropion.
Saquinavir Saquinavir The risk or severity of QTc prolongation can be increased when Granisetron is combined with Saquinavir.
Riluzole Riluzole The risk or severity of adverse effects can be increased when Riluzole is combined with Granisetron.
Ritonavir Ritonavir The serum concentration of Granisetron can be increased when it is combined with Ritonavir.
Clomipramine Clomipramine The risk or severity of QTc prolongation can be increased when Granisetron is combined with Clomipramine.
Mirtazapine Mirtazapine Granisetron may increase the serotonergic activities of Mirtazapine.
Topiramate Topiramate The risk or severity of adverse effects can be increased when Topiramate is combined with Granisetron.
Pramipexole Pramipexole Granisetron may increase the sedative activities of Pramipexole.
Donepezil Donepezil The risk or severity of adverse effects can be increased when Donepezil is combined with Granisetron.
Nelfinavir Nelfinavir The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Granisetron.
Azithromycin Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Granisetron.
Selegiline Selegiline The risk or severity of adverse effects can be increased when Granisetron is combined with Selegiline.
Sertraline Sertraline The risk or severity of adverse effects can be increased when Granisetron is combined with Sertraline.
Propafenone Propafenone The risk or severity of QTc prolongation can be increased when Granisetron is combined with Propafenone.
Ropinirole Ropinirole Granisetron may increase the sedative activities of Ropinirole.
Quetiapine Quetiapine The risk or severity of QTc prolongation can be increased when Granisetron is combined with Quetiapine.
Cetirizine Cetirizine The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Granisetron.
Paroxetine Paroxetine The risk or severity of adverse effects can be increased when Granisetron is combined with Paroxetine.
Tolcapone Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Granisetron.
Citalopram Citalopram The risk or severity of QTc prolongation can be increased when Granisetron is combined with Citalopram.
Efavirenz Efavirenz The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Granisetron.
Tolterodine Tolterodine The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Granisetron.
Thalidomide Thalidomide Granisetron may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Galantamine Galantamine The risk or severity of QTc prolongation can be increased when Galantamine is combined with Granisetron.
Levetiracetam Levetiracetam The risk or severity of adverse effects can be increased when Granisetron is combined with Levetiracetam.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists